Key Highlights

  • argenx (NASDAQ:ARGX) agreed to acquire Forte Biosciences (NASDAQ:FBRX) for $77 per share in cash, valuing the deal at approximately $2.2 billion.
  • The all-cash offer represents a premium of roughly 86% to Forte Biosciences' volume-weighted average price since its positive Phase 1b vitiligo data on July 9, 2026.
  • The acquisition adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx's immunology pipeline.
  • The deal builds on argenx's earlier strategic investment in Forte Biosciences and is expected to close in the third quarter of 2026, subject to customary closing conditions.

A Shift From Strategic Investment to Full Ownership

argenx and Forte Biosciences on Monday announced a definitive agreement under which argenx will acquire the clinical-stage biopharmaceutical company for 77 dollars per share in cash, a transaction valued at approximately 2.2 billion dollars. The deal marks a move from strategic investment to full ownership, following argenx's earlier equity stake in Forte Biosciences and reflecting growing confidence in the clinical data supporting the company's lead program.

Forte Biosciences' primary asset, FB102, is a first-in-class anti-CD122 antibody targeting pathogenic T-cell and NK-cell activity, an approach designed to address autoimmune diseases that have seen limited innovation for decades. The offer price represents a substantial premium of roughly 86 percent to Forte Biosciences' volume-weighted average share price since the company reported positive Phase 1b vitiligo results on July 9, 2026.

FB102 Broadens argenx's Immunology Franchise

The acquisition strengthens argenx's immunology portfolio by adding a differentiated mechanism to a pipeline that already includes efgartigimod, empasiprubart, adimanebart and ARGX-121, alongside several earlier-stage molecules. FB102's CD122-targeting approach broadens the company's ability to address diseases driven by different dimensions of immune system dysfunction, complementing its existing antibody-based programs rather than duplicating them.

Clinical validation played a central role in the shift from investment to acquisition. Forte Biosciences recently reported statistically significant treatment benefit in a Phase 1b vitiligo study, while earlier Phase 1b data in celiac disease showed positive results, with Phase 2 data expected in the second half of this year. Beyond these two indications, FB102 carries potential in alopecia areata and other autoimmune conditions, giving it a pipeline-in-a-product profile that could support multiple future indications from a single clinical asset.

The transaction will be funded entirely from cash on hand and is not subject to a financing condition, a structure that limits execution risk relative to deals dependent on external financing sources.

Closing Conditions and Clinical Readouts Shape the Path Forward

The deal's completion remains subject to customary closing conditions, including the tender of at least a majority of Forte Biosciences' outstanding shares and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Both boards have approved the transaction, and the companies expect the deal to close in the third quarter of 2026, though the timeline could shift depending on regulatory review and shareholder participation in the tender offer.

On the upside, successful integration could accelerate FB102's development across multiple autoimmune indications, potentially strengthening argenx's long-term growth profile beyond its existing FcRn-focused portfolio. However, clinical-stage assets carry inherent risk, and Phase 2 celiac disease data expected later this year could influence how quickly the program advances. Broader risks include potential stockholder litigation related to the transaction, a possibility the companies flagged as a factor that could affect deal costs or timing.

Conclusion

argenx's agreement to acquire Forte Biosciences for approximately 2.2 billion dollars reflects a disciplined approach to expanding its immunology pipeline through clinically validated, differentiated biology rather than early-stage speculation. The addition of FB102 broadens the company's therapeutic reach into CD122-driven autoimmune diseases, complementing its existing antibody franchise. Whether the acquisition delivers on its pipeline-in-a-product potential may depend heavily on how Phase 2 celiac disease data reads out later this year and how efficiently the combined organization can advance FB102 across vitiligo, celiac disease, alopecia areata and other indications following the deal's expected third-quarter close.